Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance. The company achieved total net product sales of $682.0 million, representing 17% year-over-year growth. INGREZZA net product sales for Q2 2025 were $624.4 million, an increase from $579.5 million in Q2 2024.
CRENESITY, in its early launch phase, contributed $53.2 million in net product sales for Q2 2025, with 664 total new patient enrollment start forms. Total revenues for the quarter reached $687.5 million, compared to $590.2 million in Q2 2024. The company reported GAAP net income of $107.5 million, or $1.06 diluted earnings per share.
As of June 30, 2025, Neurocrine maintained a strong liquidity position with $1,849.4 million in cash, cash equivalents, and marketable securities. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion - $2.55 billion and updated its GAAP SG&A expense guidance to $1,135 million - $1,155 million, while continuing to advance its neuropsychiatry pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.